PDF(Pubmed)
Abstract：
UNASSIGNED: This scientific review involves a sequential analysis of randomized trial research focused on the incidence of shivering in patients undergoing cardiac surgery. The study conducted a comprehensive search of different databases, up to the end of 2020. Only randomized trials comparing magnesium administration with either placebo or no treatment in patients expected to experience shivering were included. The primary objective was to evaluate shivering occurrence, distinguishing between patients receiving general anesthesia and those not. Secondary outcomes included serum magnesium concentrations, intubation time, post-anesthesia care unit stay, hospitalization duration, and side effects. Data collection included patient demographics and various factors related to magnesium administration.
UNASSIGNED: This scientific review analyzed 64 clinical trials meeting inclusion criteria, encompassing a total of 4303 patients. Magnesium was administered via different routes, primarily intravenous, epidural, and intraperitoneal, and compared against placebo or control. Data included demographics, magnesium dosage, administration method, and outcomes. Heterogeneity was assessed using the I2 statistic. Some studies were excluded due to unavailability of data or non-responsiveness from authors.
UNASSIGNED: and discussion: Out of 2546 initially identified articles, 64 trials were selected for analysis. IV magnesium effectively reduced shivering, with epidural and intraperitoneal routes showing even greater efficacy. IV magnesium demonstrated cost-effectiveness and a favorable safety profile, not increasing adverse effects. The exact dose-response relationship of magnesium remains unclear. The results also indicated no significant impact on sedation, extubation time, or gastrointestinal distress. However, further research is needed to determine the optimal magnesium dose and to explore its potential effects on blood pressure and heart rate, particularly regarding pruritus prevention.
UNASSIGNED: This study highlights the efficacy of intravenous (IV) magnesium in preventing shivering after cardiac surgery. Both epidural and intraperitoneal routes have shown promising results. The safety profile of magnesium administration appears favorable, as it reduces the incidence of shivering without significantly increasing costs. However, further investigation is required to establish the ideal magnesium dosage and explore its potential effects on blood pressure, heart rate, and pruritus prevention, especially in various patient groups.
UNASSIGNED: This scientific review analyzed 64 clinical trials meeting inclusion criteria, encompassing a total of 4303 patients. Magnesium was administered via different routes, primarily intravenous, epidural, and intraperitoneal, and compared against placebo or control. Data included demographics, magnesium dosage, administration method, and outcomes. Heterogeneity was assessed using the I2 statistic. Some studies were excluded due to unavailability of data or non-responsiveness from authors.
UNASSIGNED: and discussion: Out of 2546 initially identified articles, 64 trials were selected for analysis. IV magnesium effectively reduced shivering, with epidural and intraperitoneal routes showing even greater efficacy. IV magnesium demonstrated cost-effectiveness and a favorable safety profile, not increasing adverse effects. The exact dose-response relationship of magnesium remains unclear. The results also indicated no significant impact on sedation, extubation time, or gastrointestinal distress. However, further research is needed to determine the optimal magnesium dose and to explore its potential effects on blood pressure and heart rate, particularly regarding pruritus prevention.
UNASSIGNED: This study highlights the efficacy of intravenous (IV) magnesium in preventing shivering after cardiac surgery. Both epidural and intraperitoneal routes have shown promising results. The safety profile of magnesium administration appears favorable, as it reduces the incidence of shivering without significantly increasing costs. However, further investigation is required to establish the ideal magnesium dosage and explore its potential effects on blood pressure, heart rate, and pruritus prevention, especially in various patient groups.
摘要：
■这项科学综述涉及对随机试验研究的顺序分析，该研究的重点是心脏手术患者发抖的发生率。这项研究对不同的数据库进行了全面的搜索，到2020年底。仅包括在预期经历颤抖的患者中比较镁给药与安慰剂或不治疗的随机试验。主要目标是评估颤抖的发生，区分接受全身麻醉的患者和未接受全身麻醉的患者。次要结果包括血清镁浓度，插管时间,麻醉后监护病房住院，住院时间，和副作用。数据收集包括患者人口统计学和与镁施用相关的各种因素。
■本科学综述分析了64项符合纳入标准的临床试验，共包括4303名患者。镁通过不同的途径给药，主要是静脉注射，硬膜外,和腹膜内，并与安慰剂或对照进行比较。数据包括人口统计，镁用量,管理方法，和结果。使用I2统计量评估异质性。由于数据不可用或作者无反应，一些研究被排除在外。
■和讨论：在2546篇最初确定的文章中，选择64个试验进行分析。IV镁有效减少寒战，硬膜外和腹膜内途径显示出更大的疗效。IV镁证明了成本效益和良好的安全性，不增加不良影响。镁的确切剂量-反应关系尚不清楚。结果还表明对镇静没有显著影响，拔管时间,或者肠胃不适.然而,需要进一步的研究来确定最佳镁剂量，并探索其对血压和心率的潜在影响，尤其是预防瘙痒。
■这项研究强调了静脉（IV）镁在预防心脏手术后发抖中的功效。硬膜外和腹膜内途径均显示出有希望的结果。镁给药的安全性似乎很好，因为它减少了发抖的发生率，而不会显着增加成本。然而,需要进一步研究以确定理想的镁剂量并探索其对血压的潜在影响，心率,预防瘙痒，尤其是在不同的患者群体中。
■本科学综述分析了64项符合纳入标准的临床试验，共包括4303名患者。镁通过不同的途径给药，主要是静脉注射，硬膜外,和腹膜内，并与安慰剂或对照进行比较。数据包括人口统计，镁用量,管理方法，和结果。使用I2统计量评估异质性。由于数据不可用或作者无反应，一些研究被排除在外。
■和讨论：在2546篇最初确定的文章中，选择64个试验进行分析。IV镁有效减少寒战，硬膜外和腹膜内途径显示出更大的疗效。IV镁证明了成本效益和良好的安全性，不增加不良影响。镁的确切剂量-反应关系尚不清楚。结果还表明对镇静没有显著影响，拔管时间,或者肠胃不适.然而,需要进一步的研究来确定最佳镁剂量，并探索其对血压和心率的潜在影响，尤其是预防瘙痒。
■这项研究强调了静脉（IV）镁在预防心脏手术后发抖中的功效。硬膜外和腹膜内途径均显示出有希望的结果。镁给药的安全性似乎很好，因为它减少了发抖的发生率，而不会显着增加成本。然而,需要进一步研究以确定理想的镁剂量并探索其对血压的潜在影响，心率,预防瘙痒，尤其是在不同的患者群体中。
